Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Regulatory barriers to xenotransplantation

Goerlich, Corbin E.a,b; Chan, Joshua L.c; Mohiuddin, Muhammad M.a

Current Opinion in Organ Transplantation: October 2019 - Volume 24 - Issue 5 - p 522–526
doi: 10.1097/MOT.0000000000000678
XENOTRANSPLANTATION: Edited by Parsia A Vagefi
Buy

Purpose of review There is a grave discordance between supply and demand for patients with failing organs largely due to an insufficient donor pool for transplantation. Xenotransplantation has been proposed as a solution to bridge this gap.

Recent findings Recent success over the last decade in nonhuman primate models, due to emerging gene-editing technologies combined with novel immunosuppression regimens, has produced promising results in pancreatic islet cell, heart, lung, kidney and liver xenotransplantations.

Summary As the prospect of xenotransplantation is realized, safety and ethical considerations have come to the forefront of discussion. The WHO and World Health Assembly have encouraged member states to form regulatory bodies to govern human xenotransplantation studies with the highest standards. Here, we summarize the current regulatory landscape governing preclinical advances toward the first human clinical trials.

aDepartment of Surgery, Cardiac Xenotransplantation Program, University of Maryland School of Medicine

bDepartment of Surgery, Johns Hopkins Hospital, Baltimore, Maryland

cDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA

Correspondence to Muhammad M. Mohiuddin, MD, Cardiac Xenotransplantation Program, University of Maryland School of Medicine, 10 S. Pine Street, MSTF 434B, Baltimore, MD 21201, USA. Tel: +1 410 706 6081; e-mail: mmohiuddin@som.umaryland.edu

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.